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ABSTRACT
The PKCβ inhibitor enzastaurin was tested in parental neuroblastoma and 
rhabdomyosarcoma cell lines, their vincristine-resistant sub-lines, primary 
neuroblastoma cells, ABCB1-transduced, ABCG2-transduced, and p53-depleted 
cells. Enzastaurin IC50s ranged from 3.3 to 9.5 μM in cell lines and primary cells 
independently of the ABCB1, ABCG2, or p53 status. Enzastaurin 0.3125 μM interfered 
with ABCB1-mediated drug transport. PKCα and PKCβ may phosphorylate and 
activate ABCB1 under the control of p53. However, enzastaurin exerted similar 
effects on ABCB1 in the presence or absence of functional p53. Also, enzastaurin 
inhibited PKC signalling only in concentrations ≥ 1.25 μM. The investigated cell 
lines did not express PKCβ. PKCα depletion reduced PKC signalling but did not affect 
ABCB1 activity. Intracellular levels of the fluorescent ABCB1 substrate rhodamine 
123 rapidly decreased after wash-out of extracellular enzastaurin, and enzastaurin 
induced ABCB1 ATPase activity resembling the ABCB1 substrate verapamil. 
Computational docking experiments detected a direct interaction of enzastaurin 
and ABCB1. These data suggest that enzastaurin directly interferes with ABCB1 
function. Enzastaurin further inhibited ABCG2-mediated drug transport but by a 
different mechanism since it reduced ABCG2 ATPase activity. These findings are 
important for the further development of therapies combining enzastaurin with ABC 
transporter substrates.
INTRODUCTION
Enzastaurin (also known as LY317615) was 
synthesised as protein kinase C (PKC) β inhibitor based 
on the structure of staurosporine, a natural compound 
known to interfere with PKC signalling [1]. In pre-clinical 
models, enzastaurin displayed activity against cancer cells 
from different entities including carcinomas, glioblastoma, 
melanoma, and different haematological malignancies as 
well as anti-angiogenic effects [2–13]. The substance has 
been investigated for its effects against various cancer 
types in clinical trials [4, 13–22].
We had previously shown that enzastaurin 
activates glycogen synthase kinase (GSK) 3β in natural 
killer cells and in turn reduces their activity [23]. To 
test the effects of (potential) anti-cancer agents in the 
context of cellular chemoresistance mechanisms, we 
have established the Resistant Cancer Cell Line (RCCL) 
collection, a collection of cell lines from 15 different 
cancer entities with acquired resistance to various 
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cytotoxic and targeted anti-cancer drugs (http://www.
kent.ac.uk/stms/cmp/RCCL/RCCLabout.html) including 
cell lines derived from the paediatric cancer entities 
neuroblastoma and rhabdomyosarcoma. Significant 
subgroups of patients suffering from these cancers are 
high-risk patients with very poor prognosis [24–27]. 
Vincristine is a constituent of therapy regimens for 
both neuroblastoma and rhabdomyosarcoma [24–28]. 
Here, we tested enzastaurin alone or in combination 
with vincristine in a panel of parental neuroblastoma 
and rhabdomyosarcoma cell lines and their vincristine-
resistant sub-lines.
RESULTS
Influence of enzastaurin on viability of 
neuroblastoma and rhabdomyosarcoma cells
Enzastaurin interfered with the viability of 
chemosensitive and chemoresistant neuroblastoma and 
rhabdomyosarcoma cells in similar concentrations, 
enzastaurin IC50 values ranged from 3.74 to 8.20 μM 
(Table 1). Similar results were obtained in primary 
MYCN-amplified neuroblastoma cells (Table 2).
ABCB1 and ABCG2 are major ATP-binding 
cassette (ABC) transporters that are involved in the 
passage of drugs, xenobiotics, and food constituents 
through cellular and tissue barriers and consequently in 
their absorption, distribution, and excretion. Moreover, 
ABCB1 and ABCG2 are frequently found highly 
expressed on cancer cells playing an important role in 
cancer cell chemoresistance [29–31]. p53 is a major 
tumour suppressor gene. Loss-of-p53 function has been 
associated with decreased drug sensitivity in cancers 
including neuroblastoma [32, 33]. However, neither p53 
functionality nor ABCB1 or ABCG2 expression status 
significantly modified enzastaurin sensitivity of the 
investigated cell lines (Table 1).
Enzastaurin sensitises ABCB1-expressing cells to 
cytotoxic ABCB1 substrates
Next, the influence of enzastaurin was tested 
on the vincristine sensitivity of neuroblastoma and 
rhabdomyosarcoma cells. Enzastaurin 1.25 μM, a 
concentration that did not significantly affect cell line 
viability, sensitised ABCB1-expressing vincristine-
resistant cells to the ABCB1 substrate vincristine but 
did not substantially change the vincristine sensitivity 
of the respective parental cell lines that express low 
levels of ABCB1 (Figure 1A, Suppl. Table 1). Effects 
were similar in vincristine-adapted, ABCB1-expressing 
cells and in UKF-NB-3ABCB1 cells transduced with 
a lentiviral vector encoding for ABCB1 (Figure 1B, 
Suppl. Table 1).
ABCB1 recognises a broad range of structurally 
different substrates. In concordance, enzastaurin 0.625 
μM and 1.25 μM also dose-dependently sensitised 
ABCB1-expressing UKF-NB-3rVCR10 cells (that do not 
express ABCC1, ABCC2, ABCC3, ABCC5, or ABCG2, 
data not shown) to the alternative cytotoxic ABCB1 
substrates paclitaxel and actinomycin D (Figure 1C, 
Suppl. Table 2). Enzastaurin further sensitised ABCB1-
expressing UKF-NB-3rVCR10, UKF-NB-2rVCR10, 
KFRrVCR10, and Rh30rVCR10 cells (but not non-
ABCB1-expressing UKF-NB-3, UKF-NB-2, KFR, and 
Rh30 cells) to vincristine in a dose-dependent manner. 
Enzastaurin concentrations as low as 0.3125 μM were 
found to enhance vincristine activity (Figure 1D, Suppl. 
Table 3A–3D).
Finally, we investigated the influence of enzastaurin 
on the efflux of the fluorescent ABCB1 substrate 
rhodamine 123 in ABCB1-expressing UKF-NB-3rVCR10 
cells. Enzastaurin caused a concentration-dependent 
increase in rhodamine 123 fluorescence in the UKF-
NB-3rVCR10 cells (Figure 1E) but did not affect ABCB1 
expression (data not shown).
Direct interaction of enzastaurin with ABCB1
Previous reports had indicated that PKCα or PKCβ 
may promote ABCB1 function by phosphorylation [34, 
35]. Therefore, enzastaurin may affect ABCB1 function 
through direct interaction with ABCB1 and/or inhibition 
of PKC-mediated ABCB1 phosphorylation. Enzastaurin 
affected ABCB1 function in concentrations as low as 
0.3125 μM (Figure 1D, Figure 1E, Suppl. Table 3). 
Since enzastaurin was shown to inhibit PKCβ enzyme 
activity with an IC50 of 0.03 μM and PKCα activity 
with an IC50 of 0.8 μM in isolated enzyme assays [1], 
enzastaurin-mediated effects on PKCα signalling are 
unlikely to be responsible for the reduced ABCB1 activity. 
Myristoylated alanine-rich C-kinase substrate (MARCKS) 
is a PKC substrate, and MARCKS phosphorylation is a 
surrogate parameter for PKC activity [3, 4]. Enzastaurin 
inhibited MARCKS phosphorylation in UKF-NB-3rVCR10 
cells only in concentrations of 1.25 μM or higher after 
6 h of incubation. After 120 h, only an enzastaurin 
concentration of 5 μM reduced MARKS phosphorylation 
(Figure 2A). Since enzastaurin inhibits ABCB1 function 
in concentrations as low as 0.3125 μM (Figure 1D, Suppl. 
Table 3), this finding suggests that the enzastaurin-
mediated inhibition of ABCB1 function may not be the 
consequence of inhibition of PKC-mediated ABCB1 
phosphorylation.
Next, we wanted to test whether interference with 
PKC signalling is sufficient to interfere with ABCB1 
function in our model. Although we readily detected 
PKCβ in K562 cells that had served as positive control, we 
were not able to detect PKCβ in UKF-NB-3rVCR10 cells 
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(Suppl. Figure 1A). PKCα was present, and siRNA-
mediated PKCα depletion inhibited PKC signalling as 
indicated by decreased levels of phosphorylated MARCKS 
(Figure 2B, Suppl. Figure 1B). However, siRNA-mediated 
depletion of PKCα did (in contrast to ABCB1 depletion) 
not increase rhodamine 123 accumulation in or vincristine 
sensitivity of ABCB1-expressing UKF-NB-3rVCR10 
cells (Figure 2C, Suppl. Figure 1C). Similar results were 
obtained in UKF-NB-3ABCB1 cells (Suppl. Figure 2A–2C).
After incubation of UKF-NB-3rVCR10 cells 
with rhodamine 123 and enzastaurin, the wash-out of 
extracellular enzastaurin (and rhodamin 123) resulted in a 
rapid decrease of cellular rhodamine 123 fluorescence in 
a similar fashion like the wash out of the known ABCB1 
substrate verapamil (Figure 3A). In addition, enzastaurin 
0.3125 μM significantly increased ABCB1 ATPase 
activity (Figure 3B). The combination of enzastaurin 
and verapamil further enhanced ABCB1 ATPase activity 
(Figure 3C). Taken together, these data suggest that 
enzastaurin interferes with ABCB1 predominantly through 
direct interaction with ABCB1, possibly being an ABCB1 
substrate.
Table 1: Influence of enzastaurin on neuroblastoma and rhabdomyosarcoma cell viability. Expressed 
as concentration that reduces cell viability (determined by MTT assay) after a 5 day incubation period 
by 50% (IC50)
Cell line p53 status ABCB1 IC
50
(1) enzastaurin (μM)
UKF-NB-3 wild-type − (2) 6.31 ± 0.98(3)
UKF-NB-3rVCR10 mut (C135F)(4) + 5.33 ± 1.09
UKF-NB-3ABCB1 (5) wild-type + 9.46 ± 1.89
UKF-NB-3Cer2 (6) wild-type − 8.44 ± 0.95
UKF-NB-3ABCG2 (7) wild-type − 5.61 ± 1.03
UKF-NB-3iG2 (8) wild-type − 5.31 ± 0.88
UKF-NB-3p53shRNA (9) depleted − 3.53 ± 0.69
UKF-NB-3scrshRNA (10) wild-type − 4.71 ± 0.73
UKF-NB-2 wild-type − 3.74 ± 0.48
UKF-NB-2rVCR10 wild-type + 6.67 ± 1.25
KFR wild-type − 5.04 ± 0.84
KFRrVCR10 wild-type + 4.52 ± 0.71
Rh30 mut (R273C) − 6.84 ± 0.96
Rh30rVCR10 mut (R273C) + 8.20 ± 1.07
(1)concentration that reduces cell viability (determined by MTT assay) after a 5 day incubation period by 50%; (2)ABCB1 
expression levels are presented in Suppl. Table 6; (3)Values are mean ± S.D.; (4)mut=mutated, kind of mutation in brackets; 
(5)UKF-NB-3 cells transduced with a lentiviral vector encoding for the ABCB1 gene; (6)UKF-NB-3 cells transduced with an 
empty lentiviral control vector, serving as transduction control for UKF-NB-3ABCB1; (7)UKF-NB-3 cells transduced with a 
lentiviral vector encoding for the ABCG2 gene; (8)UKF-NB-3 cells transduced with an empty lentiviral control vector, serving 
as transduction control for UKF-NB-3ABCG2; (9)UKF-NB-3 cells transduced with a lentiviral vector encoding for shRNA 
directed against p53; (10)UKF-NB-3 cells transduced with a lentiviral vector encoding scrambled (non-targeted) shRNA.
Table 2: Enzastaurin concentrations that reduce viability of primary MYCN-amplified 






isolate 1 6.2 ± 2.3
isolate 2 4.4 ± 1.3
isolate 3 3.3 ± 1.4
isolate 4 7.6 ± 2.9
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Figure 1: Influence of enzastaurin on drug sensitivity in ABCB1-expressing cells. (A) Sensitisation of low and high ABCB1 
expressing cells to the ABCB1 substrate vincristine by enzastaurin 1.25 μM, a concentration that did not influence viability of the investigated 
cell lines (fold change IC50 vincristine/ IC50 vincristine in the presence of enzastaurin); (B) sensitisation of UKF-NB-3 cells transduced with 
a lentiviral vector encoding for ABCB1 (UKF-NB-3ABCB1) or an empty control vector (UKF-NB-3Cer2) to vincristine by enzastaurin 1.25 μM 
(fold change IC50 vincristine/ IC50 vincristine in the presence of enzastaurin). Numerical data for A) and B) are presented in Suppl. Table 1. 
(C) Sensitisation of UKF-NB-3rVCR10 cells to the cytotoxic ABCB1 substrates actinomycin D and paclitaxel by enzastaurin 1.25 μM 
(fold change IC50 drug alone/ IC50 drug in the presence of enzastaurin). Numerical data are presented in Suppl. Table 2. (D) Sensitisation 
of UKF-NB-3rVCR10 cells to vincristine by enzastaurin (fold change IC50 vincristine / IC50 vincristine in the presence of enzastaurin). 
Numerical data are presented in Suppl. Table 3. (E) Influence of enzastaurin on accumulation of rhodamine 123 (0.5 μM; a fluorescent 
ABCB1 substrate) in ABCB1-expressing UKF-NB-3rVCR10 cells as detected by flow cytometry (RFU = relative fluorescence units).  
*P < 0.05 relative to rhodamine alone.
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Figure 2: Investigation of PKC signalling. (A) Enzastaurin inhibits PKC activity in concentrations ≥ 1.25 μM in UKF-NB-3rVCR10 
cells after enzastaurin treatment for 6 h and in a concentration of 5 μM after 120 h. Western blots indicate protein levels of the PKC 
target MARCKS, its phosphorylated form (pMARCKS), and β-actin (loading control). Effects on ABCB1 function were observed at 
an enzastaurin concentration of 0.3125 μM (Figure 1D, Suppl. Table 3). (B) Effects of siRNA-mediated PKCα depletion on MARCKS 
phosphorylation determined in UKF-NB-3rVCR10 cells 48 h after transfection; (C) siRNA directed against ABCB1 (but not siRNA directed 
against PKCα) increases (1) accumulation of the fluorescent ABCB1 substrate rhodamine 123 (0.5 μM) in ABCB1-expressing UKF-NB-
3rVCR10 cells and (2) the sensitivity of UKF-NB-3rVCR10 cells to the cytotoxic ABCB1 substrate vincristine. Effects of siRNAs on ABCB1 
expression are presented in Suppl. Figure 1. (*P < 0.05) relative to non-targeting siRNA.
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Docking experiments suggest a direct interaction 
of enzastaurin with ABCB1
Enzastaurin was docked into the homology model 
of human ABCB1 and the three x-ray structures of mouse 
Abcb1a, with the binding sites defined using the positions 
of the co-crystallised ligands, QZ59-RRR and QZ59-SSS, 
and the verapamil binding site (residues protected from 
methanethiosulfonate (MTS) labelling by verapamil) as 
described by Aller et al. [36]. Results indicate a strong 
Figure 3: Direct interaction of enzastaurin with ABCB1. (A) Time kinetics of rhodamine 123 (0.5 μM) fluorescence in UKF-NB-
3rVCR10 cells after incubation for 60 min with rhodamine 123 alone (rhodamine control), enzastaurin 5 μM or 2.5 μM plus rhodamine 123, 
or verapamil 5 μM (known ABCB1 substrate serving as control) plus rhodamine 123 after wash-out as detected by flow cytometry (RFU = 
relative fluorescence units). *P < 0.05 relative to rhodamine alone; (B) ABCB1 ATPase activity in isolated membranes in the presence of 
verapamil 5 μM or enzastaurin. *P < 0.05 relative to non-treated control; (C) ABCB1 ATPase activity in non-treated isolated membranes or 
in the presence of verapamil 5 μM, enzastaurin 1.25 μM, or the combination of verapamil 5 μM and enzastaurin 1.25 μM. *P < 0.05 relative 
to single treatment with verapamil and enzastaurin.
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interaction between enzastaurin and ABCB1. The docking 
scores for the top five docking poses ranged between 
−16.60 and −9.01 kcal/mol for mouse, and between 
−13.30 and −10.42 kcal/mol for human ABCB1 (Suppl. 
Table 4). Docking enzastaurin into 3G60 and 3G61 
generated the lowest binding scores. The protein structures 
3G61 and 3G60 are the structures co-crystallised with 
QZ59-SSS and QZ59-RRR respectively, and have 
a x-ray resolutions of 4.35 Å and 4.40 Å. 3G5U is the 
apo-structure with a higher x-ray resolution of 3.80 Å. 
Suppl. Table 4 also shows that the best binding scores in all 
cases are achieved when the biding site is defined using the 
co-crystallised QZ59-SSS (see the average of the top five 
poses in Suppl. Table 4). The only exception to this is the 
top pose obtained for 3G60 when docked into QZ59-RRR 
binding site. The energy of the top pose can be as low as 
−16.60 when the binding site residues of QZ59-RRR have 
been selected to define the binding pocket for enzastaurin 
(Suppl. Table 4).
Suppl. Table 5 shows the ligand interaction report 
indicating specific interactions between structural elements 
of the enzastaurin structure and ABCB1 residues in the 
top docking poses. A summary of the residues involved in 
the enzastaurin interaction with mouse Abcb1a has been 
plotted in Figure 4A. The figure indicates that the most 
prevalent interacting residues in mouse Abcb1a are Phe71, 
Phe728, and Phe974. Notably, Phe728 and Phe974 are the 
amino acids reported by Aller et al. [36] to be involved 
in the QZ59-RRR binding site. These three Phe residues 
are mostly involved in π-π interactions, with fewer 
occurrences of π-H or π-cation interactions with the ligand 
(Suppl. Table 5). An example of a top scoring docking 
pose for the interaction of enzastaurin with mouse Abcb1a 
is shown in Figure 4B. The Phe residues 71, 728 and 974 
are present in the binding site with the shadows indicating 
that in the absence of the ligand these amino acids are 
highly exposed to the solvent, but the presence of the 
ligand greatly reduces the solvent accessible surface area 
(Figure 4B). In addition, there are several other lipophilic 
residues in the close proximity of the ligand with receptor 
exposure shadows indicating the possibility of several 
hydrophobic interaction points (Figure 4B). The pyridine 
ring in the ligand has a strong arene-H interaction with 
Gln721, while the pyrrole ring is engaged in H-bonding 
interaction with Ser975 (Figure 4).
Effects of enzastaurin on ABCG2
Finally, we showed that enzastaurin also 
concentration-dependently sensitised ABCG2-transduced 
UKF-NB-3 (UKF-NB-3ABCG2) cells (but not UKF-NB-3 or 
control vector-transduced UKF-NB-3iG2 cells) to toxicity 
induced by the cytotoxic ABCG2 substrate mitox-
antrone (Figure 5A, Suppl. Table 6A–6C). In addition, 
enzastaurin enhanced mitoxantrone accumulation in 
UKF-NB-3ABCG2 cells but not in UKF-NB-3iG2 cells 
as determined by flow cytometry (Figure 5B; Suppl. 
Figure 3). While enzastaurin had enhanced ABCB1 
ATPase activity, it inhibited basal and sulfasalazine-
induced ABCG2 activity (Figure 6A and 6B) indicating 
that enzastaurin inhibits ABCB1 and ABCG2 activity 
through different mechanisms.
DISCUSSION
PKC signalling was reported to be relevant in 
neuroblastoma and rhabdomyosarcoma [37–40]. In 
this report, IC50 values between 3.7 and 8.2 μM were 
determined for the PKCβ inhibitor enzastaurin in a panel 
of parental neuroblastoma and rhabdhomyosarcoma cell 
lines and their vincristine-resistant sub-lines and IC50s 
between 3.3 and 9.5 μM in primary neuroblastoma cells. 
These concentrations are in the range of those reported 
to be effective in other cancer entities [2, 6]. Notably, 
enzastaurin activity was not affected by ABC transporters 
ABCB1 or ABCG2 or the cellular p53 status. With 
regard to p53, our results are in line with a recent study 
that showed that the effects of enzastaurin monotherapy 
did not differ between HCT116p53wt and HCTp53−/− cells 
[41]. However, since enzastaurin plasma levels of 1 − 2 
μM were reported to be achievable in patients [14, 42], 
enzastaurin may rather not be a candidate for single 
therapy in neuroblastoma or rhabdomyosarcoma.
Enzastaurin concentrations as low as 0.3125 
μM sensitised ABCB1-expressing cells (but not non-
ABCB1-expressing cells) to toxicity induced by the 
ABCB1 substrate vincristine. Enzastaurin also sensi-
tised ABCB1-expressing cells to the structurally differing 
cytotoxic ABCB1 substrates paclitaxel and actinomycin 
D. Notably, enzastaurin exerted more pronounced effects 
on vincristine- and paclitaxel-mediated toxicity than on 
actinomycin D-induced toxicity. The exact molecular 
mechanisms underlying these differences are not clear. 
It is known that the mode and/or strength of ABCB1 
interaction may differ among ABCB1 substrates and 
ABCB1 modulators. Certain ABCB1 modulators 
were shown to exert differing effects on the cellular 
accumulation of distinct ABCB1 substrates [43–45].
Moreover, enzastaurin caused a dose-dependent 
accumulation of the fluorescent ABCB1 substrate 
rhodamine 123 in ABCB1-expressing cells. Again, 
significant effects were determined at an enzastaurin 
concentration of 0.3125 μM. These data indicate that 
enzastaurin interferes with ABCB1-mediated drug 
transport. This is of potential clinical relevance. ABCB1 
is expressed at virtually every tissue and organ barrier 
and influences the absorption, distribution, and excretion 
of drugs, xenobiotics, and food constituents [29, 31]. 
Therefore, enzastaurin may affect the pharmacokinetics 
of co-administered drugs including anti-cancer drugs 
and drugs non-related to cancer. Moreover, ABCB1 is 
frequently found highly expressed on cancer cells playing 
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Figure 4: Interaction of enzastaurin with ABCB1 as indicated by docking experiments. (A) 3D view of a portion of the active 
site of mouse abc1b1 (3G60) at the lowest docking energy with docked enzastaurin in the binding pocket; blue arrows in this pose indicate 
residues (Ser925, Tyr303 and Gln721) that have strong interactions with enzastaurin (limited within 4.5 Å); (B) 2D ligand interaction 
diagram for enzastaurin with mouse Abcb1a using default settings of MOE software. The polar and non-polar residues are indicated by 
pink or green coloured amino acids respectively. Hydrogen bonding is indicated by green dotted arrow, while arene-H interaction is shown 
by green dotted line. The proximity contour is the dotted line surrounding the ligand. Blue shadows in of the residues indicate the receptor 
exposure differences by the size and intensity of the quoits discs. The directions of the shadow indicate the directions of the amino acids 
towards the ligands. The blue clouds around the ligand atoms indicate that are exposed to the solvent.
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an important role in cancer cell drug resistance [30]. 
Seemingly, our data are in accordance with unpublished 
internal data from Eli Lilly [46].
Previous reports had shown that PKCα and PKCβ 
may promote ABCB1 function by phosphorylation [34, 
35]. However, other data did not support this [47, 48], and 
further reports even suggested that PKC signalling may also 
decrease ABCB1 activity [49, 50]. Our data do not suggest 
that PKCα and/or PKCβ inhibition may play a dominant role 
in the observed effects on ABCB1 function in our system 
although some contribution of effects on PKC signalling 
cannot be excluded, in particular at higher enzastaurin 
concentrations. We did not observe PKCβ expression 
in UKF-NB-3rVCR10 cells. PKCα depletion reduced 
MARCKS phosphorylation indicating inhibition of PKC 
signalling but did not affect ABCB1 function. Moreover, 
the enzastaurin IC50 for PKCα inhibition in isolated enzyme 
assay is 0.8 μM (1) and appears, thus, to be too high to 
explain effects on ABCB1 function in concentrations as low 
as 0.3125 μM. Also, enzastaurin-mediated inhibition of PKC 
signalling became only detectable at a concentration of 1.25 
μM after 6 h of incubation or 5 μM after 120 h of incubation. 
These concentrations are substantially higher than the low 
enzastaurin concentrations that affected ABCB1-mediated 
drug transport. In addition, wash-out experiments and 
determination of ABCB1 ATPase activity demonstrated 
that the enzastaurin-mediated effects closely resemble those 
of the ABCB1 substrate verapamil. Therefore, enzastaurin 
appears to interfere directly with ABCB1, possibly being 
an ABCB1 substrate. This finding is in concordance with 
data showing that staurosporine, the lead structure that 
provided the basis for the synthesis of enzastaurin [1], and 
staurosporine analogues may interfere with ABCB1 function 
independently of effects on PKC signalling [43].
In a head-to-head comparison of enzastaurin with 
staurosporine and its derivatives UCN-01, GF109203X, 
and RO-31–8220 that had previously been investigated 
for their interaction with ABCB1-mediated drug transport 
[43], enzastaurin exerted similar effects on rhodamine 123 
accumulation in ABCB1-transduced UKF-NB-3ABCB1 cells 
Figure 5: Influence of enzastaurin on ABCG2 function. (A) Sensitisation of UKF-NB-3 cells transduced with a lentiviral vector 
encoding for ABCG2 (UKF-NB-3ABCG2) to the ABCG2 substrate mitoxantrone by enzastaurin concentrations that did not influence UKF-
NB-3ABCG2 cell viability (fold change IC50 mitoxantrone/ IC50 mitoxantrone in the presence of enzastaurin), numerical data are presented in 
Suppl. Table 6; (B) Influence of enzastaurin on accumulation of mitoxantrone (40 μM; a fluorescent ABCG2 substrate) in UKF-NB-3ABCG2 
cells as detected by flow cytometry (RFU = relative fluorescence units). The ABCG2 inhibitor Ko143 (1 μM) served as positive control. 
*P < 0.05 relative to mitoxantrone alone.
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like staurosporine and UCN-01 that had previously been 
shown to interfere strongly with ABCB1-mediated drug 
transport [43]. Also in concert with previous findings [43], 
GF109203X and RO-31–8220 displayed substantially 
weaker or no effects on rhodamin 123 accumulation 
(Suppl. Figure 4A and 4B). Moreover, enzastaurin exerted 
stronger effects on rhodamin 123 accumulation than ver-
apamil in a direct comparison (Suppl. Figure 4A and 4B).
The notion that enzastaurin interacts directly with 
ABCB1 is further supported by computational docking 
studies. Recent analyses had shown that docking studies 
performed by various approaches are reliable strategies 
to identify compounds that interact directly with ABCB1 
[51–53]. From our previous studies, the docking scores 
obtained for a group of 54 substrates (including well-known 
substrates such as ivermectin and cyclosporine) had an 
average docking score of ≤ −12, like those we observed for 
enzastaurin in the 3G60 structure, while a group of 69 non-
substrates had an average score of ~ −10 kcal/mol using 
MOE software and the same docking methodology [54, 55].
Notably, the effects of PKC signalling on ABCB1 
phosphorylation and function appear to be cell type-
dependent. In ovarian carcinoma cells, antisense oligomers 
directed against PKCα and PKCβ reversed ABCB1-
mediated drug resistance [56]. In contrast, PKCβ was not 
detectable in our model system, and siRNAs targeting 
PKCα interfered with PKC signalling but not with 
ABCB1 function. Moreover, p53 was shown to suppress 
PKCα-mediated ABCB1 activation in leiomyosarcoma, 
fibrosarcoma, and osteosarcoma cells [35]. In contrast, the 
enzastaurin-mediated effects on ABCB1 function did not 
differ between p53 wild-type and p53-mutant neuroblastoma 
or rhabdomyosarcoma cells in the present study.
In addition to its interaction with ABCB1, 
enzastaurin interfered with ABCG2-mediated drug 
transport but the mode of action appears to be different. 
Figure 6: Effects of enzastaurin on the ABCG2 ATPase. (A) ABCG2 ATPase activity in isolated membranes in the presence of 
enzastaurin or the ABCG2 substrate sulfasalazine 10 μM. *P < 0.05 relative to non-treated control; (B) ABCG2 ATPase activity in non-
treated isolated membranes or in the presence of sulfasalazine 10 μM alone or in combination with enzastaurin. *P < 0.05 relative to single 
treatment with sulfasalazine.
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While enzastaurin stimulated ABCB1 ATPase activity, it 
inhibited ABCG2 ATPase activity. ABCC1 (also known 
as MRP1) is another ABC transporter that is known to be 
of clinical relevance in neuroblastoma [57]. Noteworthy, 
enzastaurin also sensitised ABCC1-expressing cells to the 
ABCC1 substrate vincristine and enhanced accumulation 
of the fluorescent ABCC1 substrate 5-CFDA in ABCC1-
expressing cells (Suppl. Figure 5A–5C). Our findings 
showing that enzastaurin interferes with ABCB1-, 
ABCG2-, and ABCC1-mediated drug transport are of 
relevance for the further development of enzastaurin 
combination therapies. Enzastaurin has been reported to 
display enhanced activity in combination with various 
anti-cancer drugs [see e.g. 11, 13, 17, 19,  41; 58–60] 
including ABCB1, ABCG2, and/or ABCC1 substrates 
such as paclitaxel [60], docetaxel [58], erlotinib [59], 
and doxorubicin [11]. In the light of the finding that 
enzastaurin interferes with the ABCB1-, ABCG2-, and 
ABCC1-mediated drug transport studies that investigate 
the combined use of enzastaurin with substrates of these 
transporters may require careful (re-)evaluation.
In conclusion, our data show that enzastaurin 
inhibits ABCB1 predominantly through direct interaction 
independently of effects on PKC signalling or the cellular 
p53 status. This finding is in particular relevant for the 
further development of therapies in which enzastaurin is 
combined with ABCB1 substrates.
MATERIALS AND METHODS
Drugs
Enzastaurin was purchased from Selleck Chemicals 
via BIOZOL GmbH (Eching, Germany). Vincristine was 
obtained from Sigma-Aldrich Chemie GmbH (Munich, 
Germany). Rhodamine 123 was purchased from Merck 
Biosciences (Darmstadt, Germany).
Cell culture
The MYCN-amplified neuroblastoma cell lines UKF-
NB-2 and UKF-NB-3 were established from INSS stage 4 
neuroblastoma patients [61, 62]. The rhabdomyosarcoma 
cell line Rh30 was kindly provided by Dr. P.J. Houghton 
(St. Jude’s Children’s Research Hospital, Memphis, 
TN). The alveolar rhabdomyosarcoma cell line KFR was 
established from a bone marrow metastasis [63]. K562 
cells were obtained from ATCC (Manassas, VA, USA).
The cell lines were adapted to growth in the presence 
of vincristine 10 ng/ml and named UKF-NB-2rVCR10 [61], 
UKF-NB-3rVCR10 [62], Rh30rVCR10 [64], KFRrVCR10 
and derived from the RCCL collection (http://www.kent.
ac.uk/stms/cmp/RCCL/RCCLabout.html).
The UKF-NB-3 sub-lines expressing ABCB1 
(UKF-NB-3ABCB1), ABCG2 (also known as BCRP, UKF-
NB-3ABCG2), or shRNA targeting p53 mRNA (UKF-NB-
3p53shRNA) were established by lentiviral transfection as 
described previously [65–68] (http://www.lentigo-vectors.
de). ABCB1 expression data for the project cell lines is 
presented in Suppl. Figure 6.
Fresh neuroblastoma cells (MYCN amplified) were 
isolated from the bone marrow aspirate of patients with 
metastasised INSS stage 4 neuroblastoma.
Cells were propagated in IMDM supplemented with 
10% foetal calf serum, 100 IU/ml penicillin and 100 mg/
ml streptomycin at 37°C.
Viability assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye 
reduction assay after 120 h incubation modified as described 
before [64].
ABC transporter expression and function
Antibodies directed against ABCB1 (Alexis 
Biochemicals via AXXORA Deutschland, Lörrach, 
Germany) or ABCG2 (Kamiya Biomedical Company, 
Seattle, WA, USA), followed by a secondary antibody 
labelled with Phycoerythrin (R&D, Wiesbaden, Germany) 
were used to detect protein expression by flow cytometry 
(FACSCalibur, BD Biosciences, Heidelberg, Germany).
To investigate ABCB1-mediated drug efflux, cells 
were pre-incubated with different concentrations of 
enzastaurin for 30 min. 0.5 μM rhodamine 123 (fluorescent 
ABCB1 substrate) was added for another 30 min. Then, 
cell culture medium was removed, cells were washed three 
times with PBS, and fresh medium containing enzastaurin 
was added. After another 45 min, cellular fluorescence was 
analysed by flow cytometry (FACSCalibur). Rhodamine 
123 was detected at the FL1 channel.
For wash out kinetic experiments, cells were 
incubated for 1 h with 0.5 μM rhodamine 123 and 
enzastaurin at the indicated concentrations. Cells were 
resuspended in supplemented medium and cellular 
fluorescence was measured after different time points (t0, t5, 
t15, t30, t60, t120 minutes) by flow cytometry (FACSCalibur).
To investigate ABCG2-mediated drug efflux, the 
same procedures were carried out. Mitoxantrone served as 
fluorescent and cytotoxic ABCG2 substrate. The ABCG2 
inhibitor Ko143 [69] was used as control substance.
The ATPase activities of ABCB1 and ABCG2 
were determined using membrane preparations (ABCB1-
Membran: BD Biosciences, Heidelberg, Germany; ABCG2 
membrane: Solvo Biotechnolgy, Budapest, Hungary) and 
an established kit (BD Biosciences, Heidelberg, Germany) 
following the manufacturer’s instruction.
PKCα expression
Antibodies directed against PKCα (abcam, 
Cambridge, UK) followed by a secondary antibody 
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labelled with Phycoerythrin (R&D, Wiesbaden, Germany) 
were used to detect protein expression by flow cytometry 
(FACSCalibur, BD Biosciences).
Western blot
Cells were lysed in Triton X-sample buffer and 
separated by SDS-PAGE. Proteins were detected using 
specific antibodies directed against β-actin (BioVision 
via BioCat GmbH, Heidelberg, Germany), PKCα (abcam, 
Cambridge, UK), PKCβ (BD Biosciences, Heidelberg, 
Germany), MARCKS (Cell Signaling Technology, 
Danvers, MA), and phosphorylated MARCKS (Cell 
Signaling Technology). Protein bands were visualised 
by enhanced chemiluminescence using a commercially 
available kit (Amersham, Freiburg, Germany).
siRNA transfection experiments
Synthetic siRNA oligonucletides targeting ABCB1 
or PRKCA (encoding for PKCα) (ON-TARGET 
plusSMART pool siRNAs) were purchased from 
Dharmacon (Lafayette, CO, USA). The non targeting 
siRNA ON-TARGET plus SMART pool (Dharmacon) was 
used as negative control. Transfections were performed 
using the NeonTM Transfection System (Invitrogen, 
Darmstadt, Germany) according to the manufacturer’s 
protocol. UKF-NB-3rVCR10 or UKF-NB-3ABCB1 cells were 
grown to about 60–80% confluence, trypsinised and 2 × 
106 cells were re-suspended in 200 μl re-suspension buffer 
containing 2.5 μM siRNA. Electroporation was performed 
in a pipette tip chamber with previously optimised 
adjustments (voltage 1400, width 20ms, 2 pulses). After 
electroporation, the cells were transferred into fibronectin 
(100 μg/ml)-coated 6-well-plates containing pre-warmed 
IMDM plus 10% foetal calf serum.
ABCB1 docking studies
The protein and ligands were prepared for docking 
in MOE (version 2012.10, Chemical Computing Group 
Inc., Montreal, Canada). Mouse Abcb1a structures, 
3G60, 3G61 and 3G5U [36] were obtained from the 
protein data bank (http://www.rcsb.org), the human 
homology model based on this structure from [70]. The 
crystal parameters were retained and all atoms of ABCB1 
were protonated and titrated using default parameters of 
the software.
To prepare the ligand for docking, atomic charges 
were initially calculated using Merck Molecular Force 
Field 94 (MMFF94) force field and then the energy 
was minimised and atomic charges were re-calculated 
using Self-Consistent Field (SCF) optimization (AM1 
Hamiltonian). Several docking experiments were 
performed for each protein using the binding site defined 
by proximity to a co-crystallised ligand and the residues 
reported by Aller et al. [36] to be involved in the binding 
pocket of cyclic-tris-(R)-valineselenazole (QZ59-RRR), 
upper binding pocket of cyclic-tris-(S)-valineselenazole 
(QZ59-SSS), lower binding pocket of QZ59-SSS, or the 
verapamil binding site (residues protected from MTS 
labelling by verapamil) as described by Aller et al [36].
In the MOE dock panel, the placement method was 
Triangle Matcher, scoring methodology was set to London 
dG as the first and the second scoring functions, and the 
final energy was evaluated using the Generalized Born 
solvation model (GB/VI) and finally, the top five best 
scoring poses were retained.
Default parameters of the software were used for 
the calculation of the ligand interactions. These were 
energy cut-off for H-bonding and ionic interactions at 
−0.5 kcal/mol and the maximum distance for non-bonded 
interactions at 4.5 Å. This docking methodology has 
been validated previously by docking the co-crystallised 
ligand, QZ59-RRR and comparing the geometries of 
the ‘docked ABCB1/QZ59-RRR’ structure with the 
structure of P-gp/QZ59-RRR complexes from x-ray 
crystallography [71]. The docking methodology using 
MOE has a built in conformational search that conducts 
a systematic search covering all combinations of angles 
on a grid if this will result in under 5000 conformers. 
Otherwise a stochastic sampling of conformations is 
conducted. In addition to this automatic conformational 
search in one of the docking experiments for each protein, 
we performed a prior conformational analysis before the 
docking and used all the resulting conformations. MOE 
conformational search was used with LowModeMD 
sampling method. This sampling method has been 
suggested as the method of choice for larger flexible 
compounds and macrocycles [70]. Using the default 
settings of the software, 74 different conformations were 
generated and used in one docking experiment for each 
of the proteins.
Statistics
Results are expressed as mean ± S.D. of at least 
three experiments. Comparisons between two groups were 
performed using Student’s t-test. Three and more groups 
were compared by ANOVA followed by the Student-
Newman-Keuls test. P values lower than 0.05 were 
considered to be significant.
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